TheEdgeResearch
Home / Stocks / XTLB

XTL Biopharmaceuticals Ltd. (XTLB)

NASDAQ Healthcare Biotechnology
$1.37 ▼ -7.43%
Market Cap
$1.3M
Sector
Healthcare
Industry
Biotechnology
Beta
0.47
52-Wk Range
1.37-5.64
CEO
Noam Band
Country
IL
Currency
USD

XTL Biopharmaceuticals Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Herzliya, TA, IL. The stock last traded at $1.37, down 7.43% on the session, giving a market capitalisation of $1.3M. On trailing twelve-month figures it carries a trailing P/E of -0.48, a net margin of 0.0%. Its beta of 0.47 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.48
Price / Sales
0.00
Price / Book
-13.67
EV / EBITDA
-3.16
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-1.06
Current ratio
0.40
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
10
IPO date
2005-09-01
Headquarters
Herzliya, TA, IL
About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, addressing systemic lupus erythematosus and Sjogren's syndrome. The company operates under a licensing agreement with Yeda Research and Development Company Limited, granting it rights for the research, development, and commercialization of hCDR1 across numerous therapeutic applications. Originally incorporated in 1993 as Xenograft Technologies Ltd., the entity rebranded as XTL Biopharmaceuticals Ltd. in July 1995 and is currently headquartered in Ramat Gan, Israel.

Comparable companies

XTL Biopharmaceuticals Ltd. is most often compared with the following Healthcare names:

AIMCYCNENSCKALAKTTAPLRZQNRXRADXTCRTVYNE
More research on XTLB
XTLB technical analysis XTLB TheEdge Score Compare against peers
Open full interactive analysis & DCF →